CA2851762C - Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) - Google Patents

Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) Download PDF

Info

Publication number
CA2851762C
CA2851762C CA2851762A CA2851762A CA2851762C CA 2851762 C CA2851762 C CA 2851762C CA 2851762 A CA2851762 A CA 2851762A CA 2851762 A CA2851762 A CA 2851762A CA 2851762 C CA2851762 C CA 2851762C
Authority
CA
Canada
Prior art keywords
antibody
seq
ceacam1
fragment
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2851762A
Other languages
English (en)
French (fr)
Other versions
CA2851762A1 (en
Inventor
Gal Markel
Tehila Ben Moshe
Yair SAPIR
Ilana MANDEL
Jacob Schachter
Rona Ortenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Tel HaShomer Medical Research Infrastructure and Services Ltd
FameWave Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Tel HaShomer Medical Research Infrastructure and Services Ltd
FameWave Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd, Tel HaShomer Medical Research Infrastructure and Services Ltd, FameWave Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of CA2851762A1 publication Critical patent/CA2851762A1/en
Application granted granted Critical
Publication of CA2851762C publication Critical patent/CA2851762C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
CA2851762A 2011-10-11 2012-10-10 Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam) Active CA2851762C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ILPCT/IL2011/000808 2011-10-11
PCT/IL2011/000808 WO2013054320A1 (en) 2011-10-11 2011-10-11 Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
PCT/IL2012/050402 WO2013054331A1 (en) 2011-10-11 2012-10-10 Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)

Publications (2)

Publication Number Publication Date
CA2851762A1 CA2851762A1 (en) 2013-04-18
CA2851762C true CA2851762C (en) 2021-11-30

Family

ID=48081453

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2851762A Active CA2851762C (en) 2011-10-11 2012-10-10 Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)

Country Status (15)

Country Link
US (3) US9771431B2 (cg-RX-API-DMAC10.html)
EP (2) EP3360899B1 (cg-RX-API-DMAC10.html)
JP (1) JP6170926B2 (cg-RX-API-DMAC10.html)
KR (1) KR102189409B1 (cg-RX-API-DMAC10.html)
CN (1) CN103987729B (cg-RX-API-DMAC10.html)
AU (1) AU2012322272C1 (cg-RX-API-DMAC10.html)
BR (1) BR112014008893B1 (cg-RX-API-DMAC10.html)
CA (1) CA2851762C (cg-RX-API-DMAC10.html)
ES (2) ES2942314T3 (cg-RX-API-DMAC10.html)
IL (1) IL231931B (cg-RX-API-DMAC10.html)
IN (1) IN2014MN00873A (cg-RX-API-DMAC10.html)
LT (1) LT2744829T (cg-RX-API-DMAC10.html)
PL (2) PL2744829T3 (cg-RX-API-DMAC10.html)
RU (1) RU2650869C2 (cg-RX-API-DMAC10.html)
WO (2) WO2013054320A1 (cg-RX-API-DMAC10.html)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735157B2 (en) * 2005-06-09 2014-05-27 Gal Markel CEACAM1 mediated protective immunity
PL2990421T3 (pl) * 2009-04-30 2018-08-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. Przeciwciała anty-ceacam1 oraz sposoby ich stosowania
US9402916B2 (en) 2011-03-17 2016-08-02 The University Of Birmingham Re-directed immunotherapy
WO2015075725A1 (en) 2013-11-25 2015-05-28 Ccam Biotherapeutics Ltd. Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
WO2015075710A1 (en) * 2013-11-25 2015-05-28 Ccam Biotherapeutics Ltd. Compositions comprising anti-ceacam1 antibodies, lymphocyte activating agents and activated lymphocytes for cancer therapy
SG11201604815RA (en) 2013-12-19 2016-07-28 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
WO2015100219A1 (en) * 2013-12-23 2015-07-02 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
WO2015101996A1 (en) * 2014-01-02 2015-07-09 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to ceacam1 and kinase inhibitors for treating braf-mutated cells
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
RS59853B1 (sr) 2014-03-14 2020-02-28 Novartis Ag Molekuli anti-lag-3 antitela i njihove upotrebe
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
SG11201606909RA (en) 2014-04-07 2016-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
AU2015254886A1 (en) * 2014-04-27 2016-11-03 Ccam Biotherapeutics Ltd. Humanized antibodies against CEACAM1
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
WO2016028896A1 (en) 2014-08-19 2016-02-25 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
AU2015317608B2 (en) 2014-09-17 2021-03-11 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CA2963281A1 (en) 2014-10-03 2016-04-07 Novartis Ag Combination therapies
IL279420B2 (en) 2014-10-08 2024-09-01 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
WO2016120331A1 (de) 2015-01-28 2016-08-04 Karl Sebastian Lang Agonistische anti-cd66cd66 antikörper für die antiviralen therapie
JP2018508481A (ja) 2015-02-02 2018-03-29 ザ ユニバーシティ オブ バーミンガム 複数のｔ細胞エピトープを有する標的化部分ペプチドエピトープ複合体
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
EP3280795B1 (en) 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
CN118726268A (zh) 2015-04-17 2024-10-01 诺华股份有限公司 改善嵌合抗原受体表达细胞的功效和扩增的方法
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
TWI859112B (zh) 2015-07-21 2024-10-21 瑞士商諾華公司 改良免疫細胞之功效及擴展之方法
SI3317301T1 (sl) 2015-07-29 2021-10-29 Novartis Ag Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
JP6905163B2 (ja) 2015-09-03 2021-07-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア サイトカイン放出症候群を予測するバイオマーカー
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
CN109069623A (zh) 2015-12-18 2018-12-21 诺华股份有限公司 靶向CD32b的抗体及其使用方法
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
US11413340B2 (en) 2015-12-22 2022-08-16 Novartis Ag Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
RU2018134771A (ru) 2016-03-04 2020-04-06 Новартис Аг Клетки, экспрессирующие множество молекул химерных антигенных рецепторов (car), и их применение
CN107345969A (zh) * 2016-05-05 2017-11-14 中国医学科学院基础医学研究所 包含afp、gp73和ceacam1的血清标记物在诊断肝脏疾病中的用途
CN107345968A (zh) * 2016-05-05 2017-11-14 中国医学科学院基础医学研究所 Cecam1蛋白作为血清标记物在诊断肝脏疾病中的用途
CN116769050A (zh) 2016-07-20 2023-09-19 犹他大学研究基金会 Cd229 car t细胞及其使用方法
WO2018019380A1 (de) * 2016-07-28 2018-02-01 Universität Duisburg-Essen Immunstimulatorische anti-ceacam1-antikörper
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
KR20190104529A (ko) 2016-12-03 2019-09-10 주노 쎄러퓨티크스 인코퍼레이티드 Car-t 세포의 조절 방법
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
KR102019913B1 (ko) * 2017-03-24 2019-09-09 재단법인 목암생명과학연구소 항-ceacam1 항체 및 이의 용도
KR102325944B1 (ko) * 2017-11-30 2021-11-12 재단법인 목암생명과학연구소 항-ceacam1 항체 및 이의 용도
US11332528B2 (en) * 2017-03-24 2022-05-17 Mogam Institute For Biomedical Research Anti-CEACAM1 antibody and use thereof
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018223101A1 (en) 2017-06-02 2018-12-06 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
CN111050545A (zh) 2017-06-29 2020-04-21 朱诺治疗学股份有限公司 评估与免疫疗法相关的毒性的小鼠模型
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
JP7447006B2 (ja) 2017-11-01 2024-03-11 ジュノー セラピューティクス インコーポレイテッド Ｂ細胞成熟抗原（ｂｃｍａ）に特異的なキメラ抗原受容体
CN111511370A (zh) 2017-11-01 2020-08-07 朱诺治疗学股份有限公司 对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
EP3724225A1 (en) 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
KR20200128014A (ko) 2018-01-31 2020-11-11 셀진 코포레이션 입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
BR112020022655A2 (pt) * 2018-05-09 2021-02-17 Good T Cells, Inc. epítopo de antígeno de superfície de células t reguladoras e anticorpo que se liga especificamente ao mesmo
CN112203725A (zh) 2018-06-13 2021-01-08 诺华股份有限公司 Bcma嵌合抗原受体及其用途
CN110684107B (zh) * 2018-07-06 2021-03-23 中国人民解放军第四军医大学 抗MG7-Ag的单克隆抗体(MGd1)及其用途
CN110684108B (zh) * 2018-07-06 2021-06-04 中国人民解放军第四军医大学 抗MG7-Ag的单克隆抗体(CEA37)及其用途
EP3856782A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
EP3856779A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd22 chimeric antigen receptor (car) therapies
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
AU2019374103A1 (en) 2018-11-01 2021-05-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
CN113271963A (zh) 2018-11-16 2021-08-17 朱诺治疗学股份有限公司 给予工程化t细胞以治疗b细胞恶性肿瘤的方法
CA3120869A1 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
CN120209144A (zh) 2018-12-07 2025-06-27 布里格姆妇女医院 人源化和亲和力成熟的抗ceacam1抗体
WO2020132654A1 (en) * 2018-12-20 2020-06-25 Albert Einstein College Of Medicine Antagonist antibodies against human immune checkpoint ceacam1 (cd66a) and formulations, kits, and methods of use thereof
KR102166982B1 (ko) * 2019-01-24 2020-10-16 가톨릭대학교 산학협력단 간암에서 CEACAM1 및 EpCAM의 상관관계 및 이를 이용한 간암 치료효과에 대한 정보를 제공하는 방법
WO2020160050A1 (en) 2019-01-29 2020-08-06 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
WO2020244528A1 (zh) * 2019-06-04 2020-12-10 上海吉倍生物技术有限公司 一种抗ceacam5的单克隆抗体及其制备方法和用途
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
AU2019473233A1 (en) * 2019-11-07 2022-04-14 Green Cross Corporation Steric epitope of CEACAM1, and anti-CEACAM1 antibody, or fragment thereof, that specifically binds to same
CA3162892A1 (en) 2019-11-26 2021-06-03 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
AU2021251265A1 (en) 2020-04-10 2022-11-03 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
EP3909601A1 (en) 2020-05-11 2021-11-17 LeukoCom GmbH A novel antibody binding specifically to human ceacam1/3/5 and use thereof
HRP20251397T1 (hr) 2020-05-19 2026-01-02 Pharmacosmos Holding A/S Spojevi koji inhibiraju kinazu ovisnu o ciklinu za liječenje medicinskih poremećaja
CN111675750B (zh) * 2020-06-11 2022-08-30 中国药科大学 针对癌胚抗原相关黏附分子ceacam的肿瘤靶向肽及其应用
AU2021306613A1 (en) 2020-07-07 2023-02-02 BioNTech SE Therapeutic RNA for HPV-positive cancer
CN112028997B (zh) * 2020-08-04 2021-08-13 中山大学附属第五医院 抗ceacam5纳米抗体
EP4100028A4 (en) 2020-08-20 2023-07-26 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF MESOTHELIN-POSITIVE CARCINOMAS
WO2022040470A1 (en) * 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
JP7657292B2 (ja) 2020-08-20 2025-04-04 エー２ バイオセラピューティクス， インコーポレイテッド Ｃｅａｃａｍ陽性がんを治療するための組成物及び方法
EP4201961A4 (en) * 2020-08-21 2024-07-03 Shanghai Genbase Biotechnology Co., Ltd. ANTIBODIES SPECIFICALLY BOUND TO GLYCOSYLATED CEACAM5
WO2022041745A1 (zh) * 2020-08-28 2022-03-03 安源医药科技（上海）有限公司 针对SARS-CoV-2冠状病毒S蛋白的抗体及其用途
EP4216946A4 (en) 2020-09-23 2024-11-13 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders
CN112457402B (zh) * 2020-10-21 2022-08-30 北京纽安博生物技术有限公司 抗ceacam6单域抗体、人源化单域抗体及其融合蛋白和应用
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
WO2022147509A1 (en) * 2021-01-04 2022-07-07 City Of Hope Prevention and treatment of steroid-resistant or gut graft-versus-host disease (gvhd)
WO2022254337A1 (en) 2021-06-01 2022-12-08 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
EP4370552A1 (en) 2021-07-13 2024-05-22 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
KR20250029137A (ko) 2022-06-22 2025-03-04 주노 쎄러퓨티크스 인코퍼레이티드 Cd19-표적화된 car t 세포의 2차 요법을 위한 치료 방법
JP2025525937A (ja) 2022-08-05 2025-08-07 ジュノー セラピューティクス インコーポレイテッド Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
JPWO2024034580A1 (cg-RX-API-DMAC10.html) * 2022-08-08 2024-02-15
KR20250046323A (ko) 2022-08-10 2025-04-02 머크 샤프 앤드 돔 엘엘씨 Nkg2d, cd16 및 ceacam5에 결합하는 단백질
CA3272953A1 (en) * 2022-11-10 2024-05-16 Famewave Ltd. ANTIBODIES AGAINST CARCINOEMBRYONIC ANTIGEN-BINDED CELL ADHESION MOLECULE 1 (CEACAM1) FOR THE PURPOSE OF INHIBITING NETOSIS-MEDIATED ACTIVITIES
JP2026500503A (ja) 2022-12-13 2026-01-07 ジュノー セラピューティクス インコーポレイテッド Ｂａｆｆ－ｒおよびｃｄ１９に特異的なキメラ抗原受容体、ならびにその方法および使用
CN120418289A (zh) 2022-12-14 2025-08-01 安斯泰来制药欧洲有限公司 结合cldn18.2和cd3的双特异性结合剂与免疫检查点抑制剂的联合疗法
WO2024165403A1 (en) 2023-02-06 2024-08-15 Philogen S.P.A. Anti-cea antibodies
WO2024213096A1 (en) * 2023-04-13 2024-10-17 Suzhou Neologics Bioscience Co., Ltd. Ceacam1-targeting antibodies and uses thereof
WO2025120867A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
WO2025120866A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025121445A1 (en) 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4348376A (en) 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6013772A (en) 1986-08-13 2000-01-11 Bayer Corporation Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
US5910573A (en) 1992-01-23 1999-06-08 Merck Patent Gesellschaft Mit Beschrankter Haftung Monomeric and dimeric antibody-fragment fusion proteins
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6294353B1 (en) 1994-10-20 2001-09-25 Morphosys Ag Targeted hetero-association of recombinant proteins to multi-functional complexes
GB9421405D0 (en) 1994-10-21 1994-12-07 Dow Chemical Co Low voc laminating formulations
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2222055A1 (en) 1995-05-23 1996-11-28 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Multimeric proteins
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
WO1999052552A1 (en) 1998-04-15 1999-10-21 Brigham & Women's Hospital, Inc. T cell inhibitory receptor compositions and uses thereof
DE19852804C1 (de) 1998-11-16 1999-12-23 Christoph Wagener Beeinflussung der Angiogenese durch CD66a
WO2001013937A1 (en) * 1999-08-26 2001-03-01 Skubitz Keith M Peptides capable of modulating the function of cd66 (ceacam) family members
DE10016877A1 (de) 2000-04-05 2001-10-18 Scintec Diagnostics Gmbh Zug (Glyko-)Proteine mit hoher Immunreaktivität sowie ein Verfahren zu ihrer Herstellung
SE0002835D0 (sv) 2000-08-07 2000-08-07 Karolinska Innovations Ab Method and kit for production of monoclonal antibodies
EP1472276A4 (en) * 2001-02-28 2007-05-09 Keith M Skubitz PEPTIDES OF SMALL SIZE CAPACITY TO MODULATE THE FUNCTION OF THE MEMBERS OF THE FAMILY OF CD66 (CEACAM)
US20030022292A1 (en) 2001-06-07 2003-01-30 Gray-Owen Scott D. Ligation of CEACAM1
US20060058257A1 (en) 2001-08-03 2006-03-16 Christoph Wagener Influencing angiogenesis using CD66a
US20050107324A1 (en) 2003-07-12 2005-05-19 Bennett C. F. Modulation of CEACAM1 expression
US20030211477A1 (en) 2002-04-05 2003-11-13 Holmes Kathryn V. Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
US20030190600A1 (en) * 2002-04-05 2003-10-09 Dana-Faber Cancer Institute Carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1) structure and uses thereof in drug identification and screening
CU23228A1 (en) 2002-04-29 2007-09-26 Ct Ingenieria Genetica Biotech FRAGMENTS OF SPECIFIC ANTIBODIES FOR THE HUMAN CARCINOEMBRIONARY ANTIGEN (CEA) SEQUENCES OF ITS VARIABLE REGIONS AND VECTORS FOR THE MICROBIAL EXPRESSION OF THE SAME
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
AU2003282752A1 (en) 2002-10-08 2004-05-04 Immunomedics, Inc. Antibody therapy
WO2004032962A1 (en) 2002-10-08 2004-04-22 Immunomedics, Inc. Combination therapy with class iii anti-cea monoclonal antibodies and therapeutic agents
CA2542215A1 (en) 2003-11-13 2005-06-02 Genentech, Inc. Screening assays and methods of tumor treatment
US7371825B2 (en) * 2004-06-30 2008-05-13 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
US8735157B2 (en) 2005-06-09 2014-05-27 Gal Markel CEACAM1 mediated protective immunity
CN101370827B (zh) * 2005-12-21 2015-10-14 麦克罗梅特股份公司 具有cea抗性的药物组合物
US20090226444A1 (en) * 2005-12-21 2009-09-10 Micromet Ag Pharmaceutical antibody compositions with resistance to soluble cea
EP1988901B1 (en) 2006-02-27 2020-01-29 Gal Markel Ceacam based antibacterial agents
EA018456B1 (ru) * 2007-07-27 2013-08-30 Имматикс Байотекнолоджиз Гмбх Новые иммуногенные эпитопы для иммунотерапии
WO2009141679A2 (en) 2007-11-05 2009-11-26 Gal Markel Ceacam1 based point-of-care cancer diagnostic
US8817788B2 (en) 2008-01-17 2014-08-26 Nec Corporation Wireless communication terminal, method, program, recording medium, and wireless communication system
PL2990421T3 (pl) * 2009-04-30 2018-08-31 Tel Hashomer Medical Research Infrastructure And Services Ltd. Przeciwciała anty-ceacam1 oraz sposoby ich stosowania
US20120122122A1 (en) 2009-07-21 2012-05-17 Tel Hashomer Medical Research Infrastructure And Services Ltd. Method of diagnosing cancer
MX339608B (es) * 2009-08-31 2016-05-31 Roche Glycart Ag Anticuerpos del antigeno carcinoembrionario (cea).
WO2011047146A2 (en) 2009-10-14 2011-04-21 Centocor Ortho Biotech Inc. Methods of affinity maturing antibodies
US8256790B2 (en) 2010-05-26 2012-09-04 William Olen Fortner Adjustable receiver hitch system
EP2800196B1 (en) 2011-12-27 2018-09-26 LG Chem, Ltd. Lithium secondary battery and preparation thereof
JP6356134B2 (ja) 2012-10-12 2018-07-11 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． 免疫応答の増強

Also Published As

Publication number Publication date
AU2012322272C1 (en) 2017-11-02
KR102189409B1 (ko) 2020-12-14
EP2744829B1 (en) 2017-12-13
IN2014MN00873A (cg-RX-API-DMAC10.html) 2015-07-03
ES2942314T3 (es) 2023-05-31
EP2744829A4 (en) 2015-06-03
IL231931B (en) 2019-06-30
EP3360899B1 (en) 2023-01-25
HK1199646A1 (en) 2015-07-10
US20140271618A1 (en) 2014-09-18
JP2015502138A (ja) 2015-01-22
CN103987729A (zh) 2014-08-13
PL2744829T3 (pl) 2018-06-29
CA2851762A1 (en) 2013-04-18
IL231931A0 (en) 2014-05-28
WO2013054331A1 (en) 2013-04-18
US11891453B2 (en) 2024-02-06
PL3360899T3 (pl) 2023-07-10
EP2744829A1 (en) 2014-06-25
JP6170926B2 (ja) 2017-07-26
KR20140069206A (ko) 2014-06-09
EP3360899A1 (en) 2018-08-15
AU2012322272A1 (en) 2014-04-10
RU2650869C2 (ru) 2018-04-17
ES2661488T3 (es) 2018-04-02
WO2013054320A1 (en) 2013-04-18
RU2014118773A (ru) 2015-11-20
LT2744829T (lt) 2018-03-26
AU2012322272B2 (en) 2017-08-17
BR112014008893B1 (pt) 2022-04-26
US20210070884A1 (en) 2021-03-11
WO2013054331A8 (en) 2014-04-10
US20170355781A1 (en) 2017-12-14
BR112014008893A2 (pt) 2017-11-28
US9771431B2 (en) 2017-09-26
CN103987729B (zh) 2017-05-31

Similar Documents

Publication Publication Date Title
US11891453B2 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (CEACAM)
US12121579B2 (en) Antibodies specific to human t-cell immunoglobulin and ITIM domain (TIGIT)
RU2745707C2 (ru) Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака
JP2019213530A (ja) 腫瘍成長および転移を阻害するための免疫調節療法との組み合わせでのセマフォリン−４ｄ阻害分子の使用
EA037613B1 (ru) Гуманизированные антитела против ceacam1
JP2020510435A (ja) 抗ｇｉｔｒ抗体およびその使用方法
CN113396160A (zh) 治疗对免疫检查点疗法具有抗性的癌症的方法和药物组合物
KR20220164787A (ko) 암 및 감염의 치료를 위한 NKp46에 대한 항체 및 이의 작제물
KR20230159823A (ko) Cd112r에 대한 항체 및 이의 용도
KR20190034238A (ko) 종양 관련 대식세포를 표적화하는 항체 및 이의 용도
RU2820275C2 (ru) Антитела, специфичные в отношении нектина-2 человека
HK1199646B (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
CA2997130C (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170920